Our results indicate that SCFAs could inhibit the progression of different breast cancer cells through the modulation of proliferative and cell cycle pathways, leading to cyclin A2- and B1-dependent cell arrest and apoptosis. This evidence concerns the gene CCNA2 and breast carcinoma.